Roche’s Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

 Roche’s Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

Roche’s Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

Shots:
  • The data contains HAVEN 3 (N=152) study evaluating Hemlibra (emicizumab) prophylaxis vs no prophylaxis with patients aged ≥12 yrs
  • HAVEN 3 results: (reduction in treated bleeds 96%/qw, 97%/q2w); (zero treated bleeds 55.6%/qw, 60%q2w); (three or fewer treated bleeds 91.7%qw, 94.3%q2w); (reduction in treated target-joint bleeds 95%)
  • The US granted Hemlibra BT&PR designations for people with haemophilia A without factor VIII, with expected approval by 4 Oct,2018
Click here to read full press release/ article | Ref: Roche  | Image:  African society of American medicine

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post